The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Treatment of dual diagnosis disorders
Abstract
PURPOSE OF REVIEW: Treatment of dual diagnosis [co-occurrence of a substance use disorder (SUD) in patients with mental illness] poses several challenges for mental health professionals. This article seeks to review the recent advances in dual diagnosis treatment with respect to pharmacotherapy and psychosocial approaches. RECENT FINDINGS: Atypical antipsychotics are commonly used for comorbid schizophrenia and SUD. Whereas there is no difference between risperidone and olanzapine, clozapine appears to have a distinct advantage in reducing psychotic symptoms as well as substance abuse (including smoking). There is emerging evidence that quetiapine is beneficial in dually diagnosed patients, particularly using alcohol, cocaine and amphetamine. A combination of naltrexone and sertraline was found to be effective in patients with depressive disorder and alcohol dependence. Effectiveness of atomoxetine is yet to be established in patients with comorbid adult attention-deficit/hyperactivity disorder with respect to decrease in substance abuse. Integrated intervention is the choice of treatment for patients with dual diagnosis. SUMMARY: In spite of the high association between substance use and psychiatric disorders, there is a surprising paucity of studies related to treatment and outcome. A few well-designed studies have been recently published and more studies of this nature are required in order to address the challenges posed in the treatment of dual disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Integrated care models, which combine SUD and mental health treatment, have demonstrated efficacy in improving outcomes for this complex population [18].”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [18]
Citations
Cites
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., Pickering, R. P., & Kaplan, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.807 · Cited by 2,889
Merikangas, K. R., Ames, M., Cui, L., Stang, P. E., Ustun, T. B., Von Korff, M., & Kessler, R. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1180 · Cited by 464
Psychosocial Approaches to Dual Diagnosis
Drake, R. E., & Mueser, K. T. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033429 · Cited by 308
Treatment of substance abusing patients with comorbid psychiatric disorders
Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2011) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.09.010 · Cited by 306
Bellack, A. S., Bennett, M. E., Gearon, J. S., Brown, C. H., & Yang, Y. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.4.426 · Cited by 285
Salloum, I. M., Cornelius, J. R., Daley, D. C., Kirisci, L., Himmelhoch, J. M., & Thase, M. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.37 · Cited by 271
Pettinati, H. M., Oslin, D. W., Kampman, K. M., Dundon, W. D., Xie, H., Gallis, T. L., Dackis, C. A., & O’Brien, C. P. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08060852 · Cited by 268
The Effects of Clozapine on Alcohol and Drug Use Disorders Among Patients With Schizophrenia
Drake, R. E., Xie, H., McHugo, G. J., & Green, A. I. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033464 · Cited by 253
Barrowclough, C., Haddock, G., Wykes, T., Beardmore, R., Conrod, P., Craig, T., Davies, L. M., Dunn, G., Eisner, E., Lewis, S. W., et al. (2010) · BMJ · doi:10.1136/bmj.c6325 · Cited by 245
Research works printed but not linked: 3
- Sattar, 2007, Valproate in the treatment of bipolar disorder and comorbid substance abuse: a 24-week open label trial., Biol Psychiatry, 61, 46S
- Erdogan, 2010, Quetiapine in substance use disorders, abuse and dependence possibility: a review in Turkish., Turk Psikiyatri Derg, 21, 167
- Hides, 2011, Does the addition of integrated cognitive behaviour therapy and motivational interviewing improve the outcomes of standard care for young people with comorbid depression and substance misuse Med J, Aust, 195, S31
Cited by
Sorted by citations
Integrated treatment of substance use and psychiatric disorders
Kelly, T. M., & Daley, D. C. (2013) · Social Work in Public Health · doi:10.1080/19371918.2013.774673 · Cited by 378
Connor, J. P., Haber, P. S., & Hall, W. D. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00122-1 · Cited by 389
Psychosocial Interventions for People With Both Severe Mental Illness and Substance Misuse
Hunt, G. E., Siegfried, N., Morley, K. C., Sitharthan, T., & Cleary, M. L. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt160 · Cited by 282
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & on behalf of the WFSBP Task Force on Treatment Guidelines for Schizophrenia (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1009163 · Cited by 147
Morisano, D., Babor, T. F., & Robaina, K. (2014) · Nordic Studies on Alcohol and Drugs · doi:10.2478/nsad-2014-0002 · Cited by 119
Psychosocial interventions for people with both severe mental illness and substance misuse
Hunt, G. E., Siegfried, N., Morley, K. C., Sitharthan, T., & Cleary, M. L. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001088.pub3 · Cited by 125
Crockford, D. N., & Addington, D. E. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720196 · Cited by 113
Psychosocial interventions for people with both severe mental illness and substance misuse
Hunt, G. E., Siegfried, N., Morley, K., Brooke-Sumner, C., & Cleary, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001088.pub4 · Cited by 105
Alsuhaibani, R., Smith, D. C., Lowrie, R., Aljhani, S., & Paudyal, V. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03188-0 · Cited by 116
Bahji, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040999 · Cited by 83
“Integrated care models, which combine SUD and mental health treatment, have demonstrated efficacy in improving outcomes for this complex population [18].”
BackgroundHeiberg, I. H., Jacobsen, B. K., Nesvåg, R., Bramness, J. G., Reichborn‐Kjennerud, T., Næss, Ø., Ystrøm, E., Hultman, C. M., & Høye, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202028 · Cited by 94
Treatment of substance use disorders with co-occurring severe mental health disorders
Murthy, P., Mahadevan, J., & Chand, P. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000510 · Cited by 76
Ruysscher, C. D., Vandevelde, S., Vanderplasschen, W., Maeyer, J. D., & Vanheule, S. (2017) · Journal of Dual Diagnosis · doi:10.1080/15504263.2017.1349977 · Cited by 82
Kronenberg, L. M., Slager-Visscher, K., Goossens, P. J. J., van den Brink, W., & van Achterberg, T. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0264-1 · Cited by 64
Kaufmann, C. N., Chen, L., Crum, R. M., & Mojtabai, R. (2013) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-013-0740-9 · Cited by 62
Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment
Clapp, P., Wackernah, R. C., & Minnick, M. (2014) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s37907 · Cited by 58
Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice
Martinotti, G., Chiappini, S., Mosca, A., Miuli, A., Santovito, M. C., Pettorruso, M., Skryabin, V. Y., Sensi, S. L., & Giannantonio, M. D. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220623092853 · Cited by 55
Schnell, T. G., Koethe, D., Krasnianski, A., Gairing, S. K., Schnell, K., Daumann, J., & Gouzoulis‐Mayfrank, E. (2014) · American Journal on Addictions · doi:10.1111/j.1521-0391.2014.12126.x · Cited by 46
Buckingham, E., Schrage, E., & Cournos, F. (2013) · Advances in Preventive Medicine · doi:10.1155/2013/690386 · Cited by 43
Brenner, P., Brandt, L., Li, G., DiBernardo, A., Bodén, R., & Reutfors, J. (2019) · Addiction · doi:10.1111/add.14866 · Cited by 43
Valeriani, G., Corazza, O., Bersani, F. S., Melcore, C., Metastasio, A., Bersani, G., & Schifano, F. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2431 · Cited by 41
‘I'm a sick person, not a bad person’: patient experiences of treatments for alcohol use disorders
Mccallum, S. L., Mikocka-Walus, A., Gaughwin, M., Andrews, J., & Turnbull, D. (2015) · Health Expectations · doi:10.1111/hex.12379 · Cited by 38
A review of Indian research on co-occurring cannabis use disorders & psychiatric disorders
Singh, S., & Balhara, Y. P. S. (2017) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_791_15 · Cited by 33
Psychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases.
Testa, A. C., Giannuzzi, R., Sollazzo, F., Petrongolo, L., Bernardini, L., & Dain, S. (2013) · PubMed · Cited by 33
Derks, E. M., Vink, J. M., Willemsen, G., van den Brink, W., & Boomsma, D. I. (2014) · Psychological Medicine · doi:10.1017/s0033291714000361 · Cited by 30
Professionals’ perception on the management of patients with dual disorders
Roncero, C., Szerman, N., Terán, A., Pino, C., Vázquez, J. M. V., Velasco, E., Dorado, M. G., & Casas, M. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s108678 · Cited by 28
Kronenberg, L. M., Goossens, P. J. J., van Etten, D. M., van Achterberg, T., & van den Brink, W. (2014) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12056 · Cited by 32
Comorbid substance use disorders in schizophrenia: A latent class approach
Kerner, B. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.006 · Cited by 26
Continuity of Care in Dual Diagnosis Treatment: Definitions, Applications, and Implications
McCallum, S., Mikocka‐Walus, A. A., Turnbull, D. A., & Andrews, J. M. (2015) · Journal of Dual Diagnosis · doi:10.1080/15504263.2015.1104930 · Cited by 26
A Review of Indian Research on Co-occurring Psychiatric Disorders and Alcohol use Disorders
Singh, S., & Balhara, Y. P. S. (2016) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.175089 · Cited by 26
Theis (2016) · doi:10.1016/j.cnur.2016.01.007 · Cited by 24
Ricci, V., Berardis, D. D., & Maina, G. (2024) · Healthcare · doi:10.3390/healthcare12030339 · Cited by 23
Emerging strategies and clinical recommendations for the management of novel depression subtypes
Chiappini, S., Sampogna, G., Ventriglio, A., Menculini, G., Ricci, V., Pettorruso, M., Volpe, U., & Martinotti, G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2470973 · Cited by 24
Medications between psychiatric and addictive disorders
Lalanne, L., Lutz, P.-É., Trojak, B., Lang, J.-P., Kieffer, B. L., & Bacon, É. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.10.009 · Cited by 24
Observational Study on Medications Prescribed to Dual-Diagnosis Outpatients
Grau‐López, L., Roncero, C., Daigre, C., Miquel, L., Barral, C., Gonzalvo, B., Francisco Collazos, D., & Casas, M. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000024 · Cited by 21
Kronenberg, L. M., Verkerk-Tamminga, R., Goossens, P. J. J., van den Brink, W., & van Achterberg, T. (2015) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2015.04.006 · Cited by 28
Barriers to retention in substance use treatment: Validation of a new, theory-based scale
Zemore, S. E., Ware, O. D., Gilbert, P. A., & Pinedo, M. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108422 · Cited by 21
Substance Use Disorders and Schizophrenia
Manseau, M. W., & Bogenschutz, M. P. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20160008 · Cited by 19
Schizophrenia and co-occurring substance use disorder: Reward, olfaction and clozapine
Mesholam‐Gately, R. I., Gibson, L. E., Seidman, L. J., & Green, A. I. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.002 · Cited by 20
Vaaramo, K., Puljula, J., Tetri, S., Juvela, S., & Hillbom, M. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304457 · Cited by 19
Timko, C., Harris, A. H. S., Jannausch, M. L., & Ilgen, M. A. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.09.010 · Cited by 18
Avery, J., Zerbo, E. A., & Ross, S. (2015) · Academic Psychiatry · doi:10.1007/s40596-015-0361-6 · Cited by 18
Sweileh, W. M. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00517-x · Cited by 17
Klimkiewicz, A., Klimkiewicz, J., Jakubczyk, A., Kieres-Salomoński, I., & Wojnar, M. (2015) · Psychiatria Polska · doi:10.12740/pp/26071 · Cited by 17
Contribution of behavioral health factors to non-AIDS-related comorbidities: an updated review
Chichetto, N. E., Polanka, B. M., So-Armah, K. A., Sung, M., Stewart, J. C., Koethe, J. R., Edelman, E. J., Tindle, H. A., & Freiberg, M. S. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00498-y · Cited by 17
Ruysscher, C. D., Vanheule, S., & Vandevelde, S. (2017) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2017.1375461 · Cited by 18
Bertin, C., Delage, N., Rolland, B., Pennel, L., Fatseas, M., Trouvin, A., Delorme, J., Chenaf, C., & Authier, N. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.015 · Cited by 17
Kishi, T., Mukai, T., Matsuda, Y., Moriwaki, M., & Iwata, N. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.07.003 · Cited by 14
Hashemzadeh, I., Navarro, J. F., & Adán, A. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110623 · Cited by 13
Spence, A. B., Michel, K. G., Wang, C., Dutton, M. A., Lee, K. A., Merenstein, D. J., Adams-Campbell, L. L., Bell, K. A., Kikkisetti, A., Doyle, A., et al. (2021) · AIDS Patient Care and STDs · doi:10.1089/apc.2020.0224 · Cited by 13
Rezansoff, S. N., Moniruzzaman, A., & Somers, J. M. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.031 · Cited by 11
Suicidal ideation in schizophrenia
Nath, S., Kalita, K. N., Baruah, A., Saraf, A. S., Mukherjee, D., & Singh, P. K. (2021) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_130_19 · Cited by 10
Tsai, J., Huang, M., Montgomery, A. E., & Elbogen, E. B. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202100001 · Cited by 10
Outcome of patients with dual diagnosis in secondary psychiatric care
Luoto, K. E., Koivukangas, A., Lassila, A., & Kampman, O. (2016) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2016.1160149 · Cited by 9
Balhara, Y. P. S., Sarkar, S., Bera, S. C., Gupta, R. G., Chawla, N., & Lal, R. (2016) · international journal high risk behaviors & addiction · doi:10.5812/ijhrba.32501 · Cited by 9
Vieira, F. D. S., Minelli, M., & Corradi-Webster, C. M. (2017) · Physis Revista de Saúde Coletiva · doi:10.1590/s0103-73312017000400020 · Cited by 8
Impact of Substance Use Disorder on Presentation of Schizophrenia
Chaudhury, S., Tikka, S. K., & Bakhla, A. K. (2016) · Dual Diagnosis Open Access · doi:10.21767/2472-5048.100007 · Cited by 9
Villalobos-Gallegos, L., Marín-Navarrete, R., Roncero, C., & González-Cantú, H. (2017) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2016-1972 · Cited by 8
Rolland, B., Deheul, S., Danel, T., Bence, C., Blanquart, M.-C., Bonord, A., Semal, R., Briand, T., Sochala, M., Dubocage, C. B., et al. (2014) · Therapies · doi:10.2515/therapie/2014210 · Cited by 7
Santorelli, M., Miuli, A., Pettorruso, M., Carlo, F. D., Berardis, D. D., Sensi, S. L., Martinotti, G., Clerici, M., & Giannantonio, M. D. (2024) · Current Neuropharmacology · doi:10.2174/1570159x23666241023115252 · Cited by 6
Madde İlişkili Psikotik Bozuklukların Tedavisinde Kullanılan Atipik Antipsikotikler
Karaoğlan, M., Kaşarcı, G., Şahin, E., & Bireller, E. (2020) · Experimed · doi:10.26650/experimed.2020.0005 · Cited by 6
Ruysscher, C. D., Vandevelde, S., Vanheule, S., Bryssinck, D., Haeck, W., & Vanderplasschen, W. (2022) · International Journal of Mental Health Systems · doi:10.1186/s13033-022-00560-9 · Cited by 5
Latent Profile Analyses of Addiction and Mental Health Problems in Two Large Samples
Coelho, S. G., Keough, M. T., Hodgins, D. C., Shead, N. W., Parmar, P. K., & Kim, H. S. A. (2023) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-022-01003-9 · Cited by 5
Psychiatric Comorbidity in Major Depressive Disorder
Kim, J., & Schwartz, T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-58131-8.00007-0 · Cited by 1
Evidence-Supported Psychosocial Treatment for Dual Disorder Patients
Moggi, F., & Öjehagen, A. (2014) · Springer eBooks · doi:10.1007/978-3-642-45375-5_18 · Cited by 5
Addressing Dual Disorders in a Medium-Term Admission Unit
Arnau, F., Benito, A., Villar, M., Ortega, M. A. M., López-Peláez, L., & Haro, G. (2021) · Brain Sciences · doi:10.3390/brainsci12010024 · Cited by 4
Benito, A., Jiménez‐Múrcia, S., Tirado-Muñoz, J., & Adán, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020730 · Cited by 3
Integrated treatment of dual disorders in The Netherlands: a qualitative study of client experiences
van Wamel, A., Lempens, A., & Neven, A. (2021) · Advances in Dual Diagnosis: Policy, practice and research in mental health and substance use · doi:10.1108/add-12-2020-0029 · Cited by 4
Dual Diagnosis and Total Hip Arthroplasty
Klement, M. R., Nickel, B. T., Bala, A., Penrose, C. T., Green, C. L., Wellman, S. S., Bolognesi, M. P., & Seyler, T. M. (2018) · Orthopedics · doi:10.3928/01477447-20180213-09 · Cited by 3
Teixeira, J., Alexandre, S., Cunha, C., Raposo, F., & Costa, J. P. (2022) · Psychiatry Research Communications · doi:10.1016/j.psycom.2022.100056 · Cited by 3
Managing treatment-resistant depression with comorbid substance use disorders
Stubbs, K. R., Bezooyen, J. V., & Tang, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00031-1 · Cited by 2
Chiappini, S., Mosca, A., Miuli, A., d'Andrea, G., Cavallotto, C., Semeraro, F., Piro, T., Vicinelli, M. C., Tucci, R., Conidi, C., et al. (2025) · Psychopathology · doi:10.1159/000547322 · Cited by 4
Associations Between Mental Disorders and Risk of Mild Cognitive Impairment
Lee, Y. J., Kim, H., Jung, J.-H., Han, K., & Jeon, H. J. (2025) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001863 · Cited by 2
Disorders due to Substance Use: Stimulants
Sevarino, K. A., & Farrell, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_26 · Cited by 3
Suchterkrankungen und komorbide psychische Störungen
Moggi, F., & Preuss, U. W. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23021-9.00019-9 · Cited by 2
Corbo, M., Martinotti, G., Aguglia, A., Salvi, V., Amerio, A., Calò, S., Fusar‐Poli, L., Serafini, G., Signorelli, M. S., Amore, M., et al. (2021) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12738 · Cited by 2
Benito, A., Jiménez‐Múrcia, S., Tirado-Muñoz, J., & Adán, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031105 · Cited by 1
Medical and Psychiatric Comorbidities: Complicating Treatment Expectations
Miller, B. J., & Buckley, P. F. (2014) · Springer eBooks · doi:10.1007/978-3-642-45257-4_4 · Cited by 1
Characteristics of Amphetamine Psychosis with Respect to the Length of Drug Exposure
Sokolova, I. M., Babina, A., & Vysotskyi, M. M. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220726141936 · Cited by 1
Ruysscher, C. D., & Goethals, I. (2024) · International handbooks of quality-of-life · doi:10.1007/978-3-031-65873-0_10 · Cited by 1
Atypical Antipsychotic Drugs in Dual Diagnosis Patients: A Review
Marín, M. (2015) · International Journal of Neurology and Neurotherapy · doi:10.23937/2378-3001/2/1/1026 · Cited by 1
Integrative Management of Complex Patients with High Comorbidity
Lake, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-15285-7_9 · Cited by 1
Oluyase, A. O., Raistrick, D., Hughes, E. A., & Lloyd, C. (2019) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-019-00861-z · Cited by 1
Stimulant use disorders and psychosis: prevalence, correlates and impacts
Sara, G. E. (2014) · The University of Queensland · doi:10.14264/uql.2015.15 · Cited by 1
Rao, R. (2022) · Advances in Dual Diagnosis · doi:10.1108/add-11-2022-049 · Cited by 1
Guest, C., & Chrisp, T. (2015) · Advances in Dual Diagnosis · doi:10.1108/add-12-2013-0031
Current Tendencies in Psychopharmacology of Dual Psychosis
Fernández, A. P., & Nicolás, M. G. (2016) · doi:10.11648/j.ijdd.20160101.12
Management of Chronic Mental Illnesses and Substance Use Disorders
Sinha, P., Garg, A., Khanna, P., & Khanna, A. (2016) · Advances in psychology, mental health, and behavioral studies (APMHBS) book series · doi:10.4018/978-1-5225-0519-8.ch006
Wirkfaktoren psychosozialer Behandlungen bei Sucht und komorbiden psychischen Störungen
Moggi, F. (2016) · Nervenheilkunde · doi:10.1055/s-0037-1616450
Suchtbehandlung bei komorbid psychischen Krankheiten
Soyka, M., & Aichmüller, C. (2016) · Nervenheilkunde · doi:10.1055/s-0037-1616452
Uitkomsten van IDDT op een dubbele-diagnoseafdeling
Neven, A. K., & Bonebakker, A. E. (2018) · Verslaving · doi:10.1007/s12501-018-0147-0
Personality in patients with dual diagnosis: The influence of severe mental illness
Arrico, M., & Julia, E. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Bertin, C., Delorme, J., Chenaf, C., & Authier, N. (2021) · Médecine de Catastrophe - Urgences Collectives · doi:10.1016/j.pxur.2020.10.007
Management of Chronic Mental Illnesses and Substance Use Disorders
Sinha, P., Garg, A., Khanna, P., & Khanna, A. (2018) · IGI Global eBooks · doi:10.4018/978-1-5225-7666-2.ch001
Management of Chronic Mental Illnesses and Substance Use Disorders
Sinha, P., Garg, A., Khanna, P., & Khanna, A. (2018) · IGI Global eBooks · doi:10.4018/978-1-5225-7122-3.ch024
Soto, C. M. D., Otálvaro-Arcila, M. E., Casadiego, J. D. C., Vélez-Gómez, P., & Berruecos, J. F. Z. (2023) · Medicina UPB · doi:10.18566/medupb.v42n1.a03
Metadata
- Authors
- Murthy, P., & Chand, P.
- Affiliations
- National Institute of Mental Health and Neurosciences (IN)
- Corresponding author
- Murthy, Pratima
- Venue
- Current Opinion in Psychiatry
- Published
- 2012-05
- Volume
- 25
- Issue
- 3
- Pages
- 194-200
- ISSN
- 0951-7367 (ISSN-L)
- OpenAlex
- W2067425226
- Cited by
- 115
- References
- 42
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 10 · 2023: 3 · 2022: 7 · 2021: 12 · 2020: 4 · 2019: 8 · 2018: 7 · 2017: 8 · 2016: 11 · 2015: 11 · 2014: 15 · 2013: 10
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- dual diagnosis, substance use disorders, psychiatric comorbidity, pharmacotherapy, psychosocial interventions, atypical antipsychotics, clozapine, risperidone, olanzapine, quetiapine, naltrexone, sertraline, atomoxetine, integrated intervention, alcoholism, smoking, cocaine, amphetamine, attention deficit hyperactivity disorder
- MeSH terms
- Mental Disorders, Drug Therapy, Combination, Humans, Narcotic Antagonists, Psychotherapy, Antipsychotic Agents, Comorbidity, Diagnosis, Dual (Psychiatry), Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
